Drug intelligence / Profile preview

Buxue Formula

Development stage: Unknown
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Buxue Formula is a Traditional Chinese Medicine (TCM) herbal preparation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is specifically designed to "tonify blood" (Buxue) and is primarily investigated for the treatment of lower-risk myelodysplastic syndrome (MDS). The formula aims to stimulate hematopoiesis and improve the bone marrow microenvironment, thereby addressing cytopenias and improving the quality of life for patients who may not yet require aggressive therapeutic interventions like chemotherapy or stem cell transplantation. It is typically administered as an oral decoction or granule formulation and is being evaluated as a monotherapy in clinical trial settings.

Other names: Buxue FangBuxue decoction

Beyond the preview

Go deeper on Buxue Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Buxue Formula.

Explore the full profile